Initiate the 16-week TPIP trial in PAH measuring pulmonary vascular resistance and 6-minute walk distance
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 19 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- Q4 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company plans to initiate this trial in the fourth quarter of 2021.”
What we found
Evidence strength A What the grades mean
Filings say study site initiation for the PAH 16-week PVR and six-minute walk trial began in late 2021, within the Q4 2021 target.
-
A Insmed Inc 10-K filed 2022-02-17
“We initiated study sites in late 2021.” ✓ confirmed on the page
-
A Insmed Inc 8-K filed 2022-02-17
“As planned, site initiation for this study began in late 2021.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- 16-week TPIP trial in PAH with up-titration once-daily dosing
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Insmed Inc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-INSM-024128 · Corrections policy